Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.4.1.2 (
acetyl-CoA carboxylase
)
2,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The fibroblast growth factors (FGFs), and the corresponding receptors, are implicated in more than just the regulation of epithelial cell proliferation and differentiation. Specifically, FGF23 is a regulator of serum inorganic phosphate levels, and mice deficient in FGF receptor-4 have altered cholesterol metabolism. The recently described
FGF19
is unusual in that it is nonmitogenic and appears to interact only with FGF receptor-4. Here, we report that
FGF19
transgenic mice had a significant and specific reduction in fat mass that resulted from an increase in energy expenditure. Further, the
FGF19
transgenic mice did not become obese or diabetic on a high fat diet. The
FGF19
transgenic mice had increased brown adipose tissue mass and decreased liver expression of
acetyl coenzyme A carboxylase
2, providing two mechanisms by which
FGF19
may increase energy expenditure. Consistent with the reduction in expression of acetyl CoA carboxylase 2, liver triglyceride levels were reduced.
...
PMID:Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. 1195 56